Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 21;13(1):75.
doi: 10.1186/s13287-022-02747-w.

Enhancement strategies for mesenchymal stem cells and related therapies

Senthilkumar Alagesan #  1 , Jack Brady #  1 , Declan Byrnes #  1 , Juan Fandiño #  1 , Claire Masterson #  1 , Sean McCarthy #  1 , John Laffey #  1   2 , Daniel O'Toole  3
Affiliations
Review

Enhancement strategies for mesenchymal stem cells and related therapies

Senthilkumar Alagesan et al. Stem Cell Res Ther. .

Abstract

Cell therapy, particularly mesenchymal stem/stromal (MSC) therapy, has been investigated for a wide variety of disease indications, particularly those with inflammatory pathologies. However, recently it has become evident that the MSC is far from a panacea. In this review we will look at current and future strategies that might overcome limitations in efficacy. Many of these take their inspiration from stem cell niche and the mechanism of MSC action in response to the injury microenvironment, or from previous gene therapy work which can now benefit from the added longevity and targeting ability of a live cell vector. We will also explore the nascent field of extracellular vesicle therapy and how we are already seeing enhancement protocols for this exciting new drug. These enhanced MSCs will lead the way in more difficult to treat diseases and restore potency where donors or manufacturing practicalities lead to diminished MSC effect.

Keywords: Cell therapy; Extracellular vesicles; Priming; Stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249. - PMC - PubMed
    1. Andrzejewska A, Lukomska B, Janowski M. Concise review: mesenchymal stem cells: from roots to boost. Stem Cells. 2019;37(7):855–864. - PMC - PubMed
    1. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252–260. - PMC - PubMed
    1. Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013;2013:130763. - PMC - PubMed
    1. Caplan H, Olson SD, Kumar A, George M, Prabhakara KS, Wenzel P, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. 2019;10:1645. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources